Dapagliflozin reduces risk for hospitalization in patients with CKD with or without diabetes

Dapagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, reduced the risk for hospitalization for any cause in patients with chronic kidney disease (CKD) with and without type 2 diabetes. The findings suggest that dapagliflozin should be considered in such patients. The study is published in Annals of Internal Medicine.

source https://medicalxpress.com/news/2022-12-dapagliflozin-hospitalization-patients-ckd-diabetes.html